Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimer’s synaptic protection therapeutic

Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimer’s synaptic protection therapeutic

Investments > €500k
United States of America
Alzheimer’s disease & other dementias
2016